The strategy

-- Make a name for itself in the competitive U.S. generic drug market, starting with a 40-mg version of Prozac

-- Go public on the New York Stock Exchange in April with the hopes of raising a war chest of $150 million

-- Bring to market various original drugs that are now in the works, and in doing so turn itself into a global player

Before it's here, it's on the Bloomberg Terminal. LEARN MORE